Ryan H. Moy, MD, PhD

Jovana Pavisic, MD in New York, NY is affiliated with Columbia University Irving Medical Center, offering a range of healthcare services. Patients can find family physicians, pediatricians, and surgeons within the network. The facility emphasizes patient care and provides options for virtual visits, ensuring accessibility and convenience. Generated from the website content

Ezra Margolin, MD is a fellowship-trained urologist specializing in kidney stone disease and benign prostatic hyperplasia (BPH). He is committed to delivering compassionate, patient-centered care and advancing the field of urology through research and education. Currently an Assistant Professor of Urology at Columbia University Irving Medical Center, Dr. Margolin completed his fellowship in Endourology and Metabolic Stone Disease at Duke University Medical Center. He completed his residency in Urology at NewYork-Presbyterian Hospital - Columbia University, and he also holds a Doctor of Medicine degree from Columbia University College of Physicians & Surgeons. Dr. Margolin’s clinical expertise is in the medical and surgical management of kidney stones and BPH. He offers comprehensive care for patients with kidney stones, including surgical stone treatment and strategies for stone prevention. He is one of the only urologists in the New York area performing laser enucleation of the prostate, considered among the most effective and durable surgeries for improving urinary symptoms in patients with BPH. Dr. Margolin's research interests include improving patient care during acute kidney stone episodes, optimizing the performance of lasers for stone treatment, and developing urological education initiatives for medical students and residents. He has been recognized for his research with numerous awards and grants, and his work has been published in prestigious journals such as The Journal of Urology, The Journal of Endourology, and Urology. Passionate about teaching, Dr. Margolin has played a key role in creating innovative educational programs, including a multi-institutional virtual urology course enrolling students across the country. He serves as a Section Editor for Current Urology Reports and is a reviewer for several leading urology journals. He is an active member of professional organizations such as the Endourological Society and the American Urological Association.

Dr. Hua-Jay “Jeff” Cherng is an assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology. He earned his medical degree from Case Western Reserve University and completed internal medicine residency at the Hospital of the University of Pennsylvania. He subsequently trained at MD Anderson Cancer Center for his hematology and oncology fellowship. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Cherng is a clinical investigator who researches non-invasive response assessment tools such as biomarkers and imaging to predict outcomes of lymphoma patients. His focus is on circulating tumor DNA (ctDNA), fragments of genetic material shed by lymphomas that can be sequenced and tracked to measure molecular response and minimal residual disease. His work on ctDNA and PET scans in lymphoma has led to publications in high-impact journals including Blood, Blood Advances, American Journal of Hematology, and British Journal of Haematology. He has earned abstract merit awards from the American Society of Hematology, American Society of Clinical Oncology, and Pan Pacific Lymphoma Conference. His accomplishments during fellowship earned him a Waun Ki Hong Award for Achievement in Clinical Investigation. He has participated in the Academy of Next Wave of Investigators for non-Hodgkin’s lymphoma and the American Society of Hematology Clinical Research Training Institute. His research on ctDNA has been funded by a Conquer Cancer Young Investigator Award and Career Development Award as well as a NIH/NCI R03 Small Research Grant. He is a member of the SWOG Lymphoma Working Group and Committee. Dr. Cherng’s designs clinical trials with treatment guided by ctDNA; this would allow for treatment de-escalation in good responders to minimize toxicity and escalation in poor responders to maximize chance for durable remissions. Dr. Cherng sees patients with all types of lymphoma with an emphasis on aggressive non-Hodgkin B-cell lymphomas. He treats patients with standard-of-care treatments as well as on clinical trial protocols.